Stocks Under Scanner in the Biotech Space -- Axovant Sciences, Gilead Sciences, Novavax, and Opko Health

Wednesday, November 1, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, November 1, 2017 /PRNewswire/ --

If you want a Stock Review on AXON, GILD, NVAX, or OPK then come over

to http://dailystocktracker.com/register/ and sign up for your free customized report. On Tuesday, October 31, 2017, the NASDAQ Composite ended the trading session at 6,727.67, up 0.43%; the Dow Jones Industrial Average
edged 0.12% higher, to finish at 23,377.24; and the S&P 500 closed at 2,575.26, slightly advancing 0.09%. Gains were broad based as seven out of nine sectors ended the day in positive. This Wednesday, DailyStockTracker.com has initiated reports coverage on the following Biotechnology equities: Axovant Sciences Ltd (NASDAQ: AXON), Gilead Sciences Inc. (NASDAQ: GILD), Novavax Inc. (NASDAQ: NVAX), and Opko Health Inc. (NASDAQ: OPK). Take a look at the free research reports issued today on DailyStockTracker.com for these stocks by signing up at:

http://dailystocktracker.com/register/

Axovant Sciences 

London, the UK-based Axovant Sciences Ltd's stock finished Tuesday's session 1.95% higher at $5.24 with a total trading volume of 997,146 shares. The stock is trading below its 50-day moving average by 62.04%. Additionally, shares of Axovant Sciences, which engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the US and Europe, have a Relative Strength Index (RSI) of 27.31. Sign up and read the free research report on AXON at:

http://dailystocktracker.com/registration/?symbol=AXON

Gilead Sciences 

On Tuesday, shares in Foster City, California headquartered Gilead Sciences Inc. recorded a trading volume of 8.46 million shares. The stock ended the session 1.36% lower at $74.96. The Company's shares have advanced 4.68% on an YTD basis. The stock is trading above its 200-day moving average by 4.15%. Moreover, shares of Gilead Sciences, which discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and Middle-East, have an RSI of 24.99.

On October 11th, 2017, research firm Barclays resumed its 'Overweight' rating on the Company's stock, with a target price of $90 per share. The complimentary research report on GILD can be downloaded at:

http://dailystocktracker.com/registration/?symbol=GILD

Novavax 

Gaithersburg, Maryland headquartered Novavax Inc.'s shares closed the day 6.86% higher at $1.09. The stock recorded a trading volume of 7.06 million shares, which was above its three months average volume of 4.32 million shares. The Company's shares have gained 12.94% over the previous three months. The stock is trading below its 50-day moving average by 1.66%. Additionally, shares of Novavax, which focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, have an RSI of 50.79.

On October 31st, 2017, research firm Citigroup upgraded the Company's stock rating from 'Neutral' to 'Buy'. Register for free on DailyStockTracker.com and access the latest report on NVAX at:

http://dailystocktracker.com/registration/?symbol=NVAX

Opko Health 

Shares in Miami, Florida headquartered Opko Health Inc. finished 1.61% lower at $6.73. The stock recorded a trading volume of 3.58 million shares. The Company's shares have advanced 9.97% in the previous three months. The stock is trading above its 50-day moving average by 2.43%. Furthermore, shares of Opko Health, which engages in the diagnostics and pharmaceuticals business in the US, Ireland, Chile, Spain, Israel, and Mexico, have an RSI of 48.35. Get free access to your research report on OPK at:

http://dailystocktracker.com/registration/?symbol=OPK

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store